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Angiogenesis, ie, the formation of new vessels from pre‐existing one, is
a complex process tightly regulated by the dynamic balance between
pro‐angiogenic and anti‐angiogenic factors. Among pro‐angiogenic
factors, angiopoietin‐2 (Ang2) is a 75 kDa secreted glycoprotein able
to bind the receptor tyrosine kinaseTie‐2. Ang2 is a destabilizing factor
able to revert vessels to a more plastic state and works in concert with
vascular endothelial growth factor (VEGF) to determine angiogenic
remodeling and sprouting.1
Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
the Western countries. Higher density of microvessels was detected in
CLL patients with poor prognosis.2 Moreover, CLL cells are able to
secrete several pro‐angiogenic factors, such as VEGF, Ang2,
endothelin‐1 (ET‐1), and basic fibroblast growth factor (bFGF), that
can be measured at high concentration in plasma samples of CLL
patients, being also particularly increased in cases with unfavorable
prognostic factors and worse clinical outcome.3 In particular, Ang2
plasma levels are able to predict progression‐free survival of CLL
patients.4
Tie‐1 and Tie‐2 (also known as TEK) are type 1 transmembrane
protein receptor tyrosine kinases (RTKs) that interact on the cellular
surface through their ectodomains forming an inhibitory complex of sig-
nal transduction. Both Ang2 and Ang1 bind to the same site on Tie‐2,
however Ang1 induces dissociation of Tie‐1/Tie‐2 complex, clustering
of Tie‐2 and signaling initiation, whereas Ang2 inhibits Tie‐2 signaling
acting as a competitive antagonist.1,5-7 Nevertheless, when the balance
between angiopoietins is shifted to Ang2, it can also act as agonist, acti-
vating Tie‐2 receptor and downstream pathways including PI3K‐Akt
prosurvival cascade.6,8 CLL cells were reported to express Tie‐1 but
not Tie‐2.9,10Here, wewonderedwhether Ang2may act in an autocrine
fashion in CLL cells, investigating the expression of Tie‐2 receptor in
leukemic cells and the in vitro effect of Ang2 on CLL survival. All
patients included in this study (n = 38) were seen at the Hematology
Division of Modena in Italy and provided informed consent in accor-
dancewith local institutional review board requirements and the Decla-
ration of Helsinki Principles. Clinical and biological data were provided
inTable S1.
First, we measured the percentage of circulating CLL cells show-
ing expression of Tie‐2 receptor on the cellular surface in 27
untreated patients by flow cytometry, staining peripheral blood
mononuclear cells (PBMCs) using APC‐conjugated anti‐CD19Hematological Oncology. 2017;1–4. wileyonlinelibrary.com/journaantibody (Becton Dickinson), FITC‐conjugated anti‐CD5 antibody
(Dako), and PE‐conjugated anti‐Tie‐2 (R&D). The mean percentage
of CD5+/CD19+ CLL cells positive for Tie‐2 expression was 1.35%,
ranging from 0.20% to 7.31% (Figure 1A). This suggests that only a
small fraction of CLL cells effectively exposes Tie‐2 receptor on the
cellular surface. Since it was reported that activation of Tie‐2
resulted in its rapid internalization,5 we also performed an intracellu-
lar staining of Tie‐2 receptor in CLL cells (n = 13), effectively finding
that leukemic cells are moderately positive for Tie‐2 receptor (mean
fluorescence intensity ratio, MFIR, mean 1.7, range 1.1‐3.1) (Figure 1
B). No correlation between the percentage of CLL positive for Tie‐2
and the intensity of intracellular Tie‐2 was detected (n = 9, P = .39,
Figure 1C). CLL cells also express Tie‐1 receptor at higher levels than
Tie‐2 (n = 7, P = .008, Figure 1D). Immunofluorescence stainings of
CLL cells purified by immunomagnetic selection confirm a moderate
positivity for Tie‐2 receptor in 83.1 ± 4.4% of cells (mean ± SEM,
n = 5) (Figure S1). In addition, CLL cells infiltrating lymph nodes also
express Tie‐2 receptor (Figure 1E‐G).
We then purified CLL cells from PBMCs of 8 patients by
immunomagnetic selection using CD19 Microbeads (Miltenyi Biotec)
inspecting Tie‐2 protein by western blot (Figure 1H). CLL cells
expressed Tie‐2 protein at low levels with two bands at 136 and
125 KDa, lacking the 145 KDa Tie‐2 isoform that is present in the
HUVEC cells (positive control). Tie‐2 mRNA was amplified in all
CLL samples (Figure 1I) by the following primers (forward, 5′‐
GAGAAGCCCCTGAACTGTGA‐3′; reverse, 5′‐GCAAATGATGGCCT
CTCATAA‐3′) and the Tie‐2 amplicon was confirmed by direct
sequencing (data not shown).
We then argue if Ang2 may modulate Tie‐2 in CLL. Tie‐2 expres-
sion was inspected in 7 CLL samples treated with 200 ng/mL Ang2
for 24 hours, finding a slight Tie‐2 decrease upon stimulation (P = .03,
Figure 2A). In line with this result, Ang2 mRNA levels measured in puri-
fied CLL cells show an inverse correlation with the extent of Tie‐2
protein (P = .003, Figure 2B).
Altogether, these findings imply that Ang2 may act in CLL cells by
directly binding Tie‐2 receptor. Thus, we treated purified CLL cells in a
time‐course experiment with 200 ng/mL recombinant Ang2 measuring
CLL viability by flow cytometry. Overall, we found that Ang2 promotes
CLL survival (n = 11) after 96 hours of treatment from 100% (normal-
ized control) to 158% (P = .01, Figure 2C). In detail, two different
behaviors emerged in CLL cases: one group (n = 4) showed early pro‐
survival response upon Ang2 stimulation (+18% after 1 day andCopyright © 2017 John Wiley & Sons, Ltd.l/hon 1
FIGURE 1 CLL cells express Tie‐2 receptor. A, PBMCs from 27 untreated CLL patients were stained by using APC‐conjugated anti‐CD19
antibody, FITC‐conjugated anti‐CD5 antibody, and PE‐conjugated anti–Tie‐2 and analyzed by flow cytometry. Distribution of the
percentage of Tie‐2 positive cells among CLL cells is depicted on the left. The horizontal dashed line indicates the mean level. On the right,
one representative dot plot showing CD5+/CD19+/Tie‐2+ cells. B, On the left, the mean fluorescence intensity ratios (MFIR), calculated by
dividing the mean fluorescence intensity (MFI) of Tie‐2 to MFI of isotype control measured by intracellular staining, for 13 CLL samples are
depicted. On the right, histograms represent 3 representative CLL samples stained with APC‐conjugated anti‐CD19 antibody and FITC‐
conjugated anti‐CD5 antibody, then permeabilized and stained with PE‐conjugated anti‐Tie‐2. CLL cells are moderately positive for Tie‐2. For
each sample an isotype control was analyzed in parallel. The mean fluorescence intensity (MFI) is indicated in the histograms. C, Scatter plot
shows the percentage of CLL cells positive for Tie‐2 in the X‐axis and the MFIR of intracellular Tie‐2 in the Y‐axis for the same patient (n = 9).
No significant correlation is found between the 2 variables, P = .32. D, CLL cells express Tie‐1 receptor at higher levels than Tie‐2.
Connections indicated Tie‐1 and Tie‐2 MFIR of the same patient defined by flow cytometry using intracellular staining. **P < .01, n = 7. E‐F,
Double‐marker immunohistochemical analysis for Tie‐2 and CD34 shows expression of Tie‐2 on CLL cells (red signal) and scattered elements
with perivascular distribution (brown signal); scale bars, 50 μm (panel E); scale bars, 30 μm (panel F). G, Immunofluorescence co‐localization
analysis for the CLL marker CD20 (green signal) and Tie‐2 (red signal) showed that besides cells associated with vessels (white arrow), the
latter marked diffuse though variable the neoplastic cells; scale bars, 50 μm. H, Immunoblot of 8 purified CLL samples, a negative control (T
cells purified from healthy donor) and positive control (HUVEC cells) stained with Tie‐2 (D9D10) rabbit mAb (#7403) and β‐actin. I,
Amplification of 5 purified CLL samples shows positive Tie‐2 transcript in all cases
2 LETTER TO THE EDITOR+62% after 4 days), whereas the remaining 7 CLL cases displayed a late
in time survival increase upon Ang2 (+56% after 4 days) with an
irrelevant induction of CLL apoptosis to 97% after 24 and 48 hours
of treatment (Figure 2D). This 3% induction of apoptosis by Ang2
treatment after 1 day is in line with data obtained in a previous
study,10 not confirming however an effective pro‐apoptotic induction
of Ang2 after long‐time culture. We could not identify any factors, as
classical biologic prognostic factors or the extent of Tie‐2 expression,
able to identify these two different subsets. Anyway, both CLL subsets
seem to be sensitive to the pro‐survival effect of Ang2.
We then starved CLL cells for 1 hour at 37°C, then stimulating
cells with 200 ng/mL Ang2 for 20 minutes. As shown in Figure 2E,Ang2 stimulates PI3K‐AKT signaling pathway as demonstrated by
anti‐phospho‐AKT mAb (Ser 473) staining of CLL cells.
Lastly, we tried to interfere with Ang2 signaling cascade by pre‐
treating purified CLL cells with 10 μM Tie‐2 kinase inhibitor (4‐(5‐(6‐
methoxynaphthalen‐2‐yl)‐2‐(4‐(methylsulfinyl)phenyl)‐1H‐imidazol‐4‐
yl)pyridine, Selleck Chemicals) for 30 minutes at 37°C. AKT
phosphorylation at serine 473 was significantly reduced by Tie‐2
kinase inhibitor (Figure 2F) that was also able to promote CLL
apoptosis (n = 6) from 100% (untreated control) to 69% just after
24 hours (Figure 2G, P = .004).
In conclusion, our findings indicate that CLL cells express Tie‐2
receptor and that Ang2 stimulation mediates survival signals, implying
FIGURE 2 Tie‐2 kinase inhibitor reduces CLL survival. A, CLL samples (n = 7) were cultured in presence of 200 ng/mL Ang2 for 24 hours, then
inspecting Tie‐2 expression by flow cytometry. Connections indicate the MFIR for control and Ang2‐treated cells for the same patient. Ang2
induces a slight decrease in Tie‐2 expression (P = .03). B, Scatter plot depicts Ang2 mRNA levels quantified by real‐time PCR in purified CLL cells
from 7 patients in X‐axis (log scale) and the correspondent MFIR relative toTie‐2 expression measured by flow cytometry on the same cells in the
Y‐axis. An inverse correlation between variables is present (Spearman rho, r = 0.919, P = .003). C, Purified CLL cells were stimulated with Ang2
200 ng/mL for 4 days and viability was assessed by Annexin V‐PI staining. Mean relative viability is calculated by dividing the percentage of viable
cells (Annexin V‐/PI‐) of Ang2‐stimulated sample to the percentage of unstimulated control (normalized to 100%). Normalization of viability data
was necessary due to the extremely variable CLL cell survival in culture condition in each individual patient. Histograms represent mean ± standard
error of the mean (SEM) of 11 CLL samples evaluated in 3 independent experiments (P* < .05). D, CLL patients were divided into two subsets: early
responders (n = 4) and late responders (n = 7), on the basis of the timing of response to Ang2 stimulation. Mean relative viability of both subsets is
depicted from 24 to 96 hours. Unstimulated control is set at 100% (dashed line). E, Western blot analysis shows the induction of AKT
phosphorylation in CLL cells treated for 20 minutes with Ang2 (200 ng/mL). Above, bar diagram depicts densitometric quantification of bands
relative to pAKT/tot AKT ratio normalized on β‐actin (n = 3, P* < .05). F, CLL cells were pre‐treated or not with 10 μM Tie‐2 kinase inhibitor, then
stimulated or not with Ang2 (200 ng/mL). Immunoblots show the reduction in AKT phosphorylation in 2 representative CLL cases. G, Histograms
represent mean relative viability ± SEM of 6 CLL samples treated with Tie‐2 inhibitor for 24 hours and evaluated in 3 independent experiments,
showing a significant reduction of viable CLL cells (P* < .05)
LETTER TO THE EDITOR 3an autocrine role of Ang2 in CLL. The interference with Ang–Tie‐2
signaling promotes CLL apoptosis. In light of the higher levels of
Ang2 in CLL patients with more aggressive disease and adverse prog-
nostic factors, our study provides a rationale to explore novel potential
therapeutic strategies targeting Tie‐2 in CLL patients.
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